Because autocrine HGF-MET signaling has been previously shown to play a critical role in lung cancer progression [54] and co-overexpression of HGF with MET is not uncommon [55], it is attractive to propose targeting HGF-MET also as a potential strategy to curb resistance to EGFR-TKIs. The gene discussed is HGF; the disease is lung cancer.